Taxotere Lawsuits: WOmen suffered permanent hair loss from Chemo Drug taxotere
Federal multi-district litigation is about to get underway in the US District Court in New Orleans for the recently consolidated product liability lawsuits alleging that the chemo drug Taxotere caused permanent hair loss.
Before the MDL was created, lawsuits had began to be filed in Federal courts across the country, alleging that Taxotere caused permanent hair loss (alopecia) in women. Although hair loss is a common temporary side effect of chemotherapy, permanent alopecia is not.
These suits allege that the manufacturer (Sanofi) failed to update the warnings for Taxotere, failed to show the results of additional studies despite learning the facts about the risks of Taxotere, fraudulently concealed the fact that Taxotere caused permanent alopecia unlike other chemo drugs used for the treatment of breast cancer and engaged in a fraudulent marketing scheme, which involved paying kickbacks and providing other unlawful incentives to entice physicians to prescribe Taxotere.
These cases have now been consolidated into the Federal court for the Eastern District of Louisiana. About 90 cases are pending in the MDL In Re: Taxotere (Docetaxel) Products Liability Litigation – MDL No. 2740. US District Judge Kurt D. Engelhardt issued Pretrial Order 1 on October 13, 2016, announcing that he will convene the Initial Case Management Conference on November 10, 2016. The order directs that the parties submit proposed discovery plans that contain expert discovery deadlines, and a suggested schedule for joinder of parties, amendment of pleadings and consideration of class action allegations by November 2nd.
Although Taxotere has been on the market for two decades, it was only in December 2015 that the manufacturer began warning women in the US about the possibility of permanent hair loss.
The attorneys at TheLawFirm.com will continue to monitor the orders issued by the Court.
Call for a Free Consultation.
Breast cancer survivors suffered Permanent Hair Loss after Taking Taxotere?
Surviving breast cancer takes an incredible amount of courage and determination. But even if you’ve been declared cancer-free, you might still be suffering.
Permanently losing your hair can be an ordeal of its own. Permanent hair loss in women is a serious issue that can negatively affect your physical and emotional life in many ways.
If you’ve had breast cancer, there’s a 75% chance that your doctor prescribed you the chemotherapy drug Taxotere.
If you’ve taken Taxotere, there’s a 6.3% chance that you’ve suffered permanent hair loss.
We believe that the fear of cancer is so strong that the manufacturer exploited it to push this drug. However, breast cancer is highly survivable. In fact, the average 5-year survival rate for people with breast cancer is 89%. The 10-year rate is 83%, and the 15-year rate is 78%.
If the cancer is located only in the breast, the 5-year relative survival rate of people with breast cancer is 99%.
Sixty-one percent (61%) of cases are diagnosed at this stage. If the cancer has spread to the regional lymph nodes,
the 5-year survival rate is 85%. If the cancer has spread to a distant part of the body, the 5-year survival rate is 26%.
We expect thousands of lawsuits because Taxotere is so widely used and a significant percentage of women experience permanent hair loss.
If you or a loved one survived Stage I, II or III breast cancer and were treated with IV Taxotere® before December 2015 and now suffers from permanent hair loss, please contact TheLawFirm.com to discuss your potential claim.
If you’ve suffered permanent hair loss and you want to do something about it, contact TheLawFirm.com.
Negative Side Effects of Taxotere And What The Manufacturers Knew About them
As lawsuit after lawsuit has claimed, the maker of Taxotere knew that the drug could cause permanent hair loss, but the company withheld this crucial health information from patients and doctors.
Taxotere is a brand of docetaxel, a chemotherapy drug that has been used for decades in the treatment of breast, prostate, and other cancers. But not all forms of docetaxel are created equal.
Major pharmaceutical companies (aka “Big Pharma”) have deep pockets, which means they spend a lot of money on marketing their proprietary drugs. Sanofi-Aventis, the French pharmaceutical giant that developed Taxotere, has aggressively promoted it as safer and more effective than other chemotherapy drugs.
But there’s a growing body of evidence that suggests Sanofi-Aventis was lying to patients and doctors about Taxotere’s negative side effects.
In fact, Sanofi-Aventis warned patients and doctors in other countries of the fact that Taxotere could cause permanent hair loss. But they withheld that information from breast cancer victims and their doctors in America.
Maybe it had something to do with the fact that, in 1994, the U.S. Food and Drug Administration (FDA) initially rejected Taxotere for being too toxic. Sanofi-Aventis used all of its influence to ram the drug through the FDA approval process just two years later.
The attorneys at TheLawFirm.com believe that the manufacturer of Taxotere deliberately withheld vital medical information from patients and doctors – all in the name of profit.
We believe that Sanofi-Aventis had full knowledge that Taxotere could cause permanent hair loss, and that the company failed to adequately warn patients or doctors of this painful side effect. We believe that, in most cases, an alternative chemotherapy drug could have been used in place of Taxotere, and that those replacement drugs were safer and would have caused no such side effect.
If you’re a victim of Taxotere’s side effects, and you want to speak to a qualified attorney, contact TheLawFirm.com. We specialize in Taxotere cases.
Contact us today for a 100% no-cost, risk-free evaluation.
Numerous lawsuits have been filed against Sanofi-Aventis, most of them on the grounds that the drug manufacturer failed to warn patients and doctors that Taxotere could cause permanent hair loss.
At the moment, all eyes are on Louisiana for the latest developments in Taxotere litigation. More than 90 cases are currently under consideration by a Louisiana judge in what is known as a multi-district litigation, or MDL. We are experts in such cases, and will continue to study the developments in Louisiana and elsewhere.
Health organizations in other countries have stopped prescribing Taxotere because of its serious side effects.
One of the world’s leading cancer-treatment centers, the Institut Curie in Paris, recently discontinued using Taxotere to treat breast cancer. The reason: five fatal cases involving patients who had been taking the drug.
Despite such warning signs, Taxotere is still prescribed in the U.S. and Canada. If your health has been compromised by Taxotere, don’t hesitate to contact the expert attorneys at TheLawFirm.com.
Where Taxotere Fell Short and why the lawsuits?
ThelawFirm.com attorneys are actively investigating the cancer drug Taxotere.
To be honest, we were incredibly skeptical when we heard about this. We heard that it is a drug used to treat cancer victims and it can cause permanent hair loss.
Click on our Taxotere FAQ's video below for more detailed information.
Our initial thought was that if it saved a life who could complain? Hair loss seems like a silly thing to sue over if you are alive because of the drug.
However, as we investigated a little more, we learned additional facts that now suggest our initial reaction was not correct.
• The first thing to know is that cancer is not an automatic death sentence.
• Yes, it is incredibly scary. But the mortality rate of many cancers, if caught early, is actually quite low.
• For example, the 5-year relative survival rate for women with stage 0 or stage I breast cancer is close to 100%. For women with stage II breast cancer, the 5-year relative survival rate is about 93%. Other cancers are equally survivable.
Therefore, the premise that you need a particular drug just to stay alive is wrong.
That is where our initial reaction started to unravel. What we discovered was that an equally effective drug was available that did not cause permanent hair loss.
What makes this ugly is that the manufacturer of Taxotere did not warn anyone.
This is particularly harmful to women. If a man goes bald, it is not necessarily a big deal. But if you are a 35 year old woman who has stage I breast cancer and take Taxotere and then go bald for life (and long after your cancer is gone) that IS a big deal.
What makes it worse is that in Europe and Canada the manufacturer started warning patients about the possibility of permanent hair loss. So why not in the United States? Why not at least give women the choice?
That is often the complaint from TheLawFirm.com. Talcum powder is another perfect example. Even if the possibility is small, why doesn’t Johnson and Johnson at least tell women that there is some chance that using talcum powder can cause ovarian cancer? Allow them to choose to use it.
Taxotere Lawsuit News
Update: May 19, 2017
There are now over 1000 lawsuits filed in the Taxotere MDL. About half of these cases involve generic and quasi-generic manufacturers. The attorneys at TheLawFirm.com have written before about the challenges that generic drugs can pose. We have now learned that the U.S. Judicial Panel on Multidistrict Litigation (JPMDL) has allowed claims involving generic docetaxel to be included in the Taxotere MDL.
Judge Sarah S. Vance, Chair of the JPMDL, stated in a letter that the consolidated litigation does include lawsuits against both name-brand and generic forms of the drug. Taxotere, manufactured by Sanofi, lost its patent protection in late 2010. The plaintiffs charge that they experienced permanent hair loss following treatment with Taxotere. While Taxotere was first approved to treat breast cancer in 1996, it wasn’t until December 2015 that mention of permanent alopecia (hair loss) was included on the drug’s U.S. label.
While hair loss is a common side effect of chemotherapy, the plaintiffs allege that Taxotere is more likely to result in the permanent loss of hair compared to other equally effective drugs. They also claim that Sanofi-Aventis has long provided information about the potential for permanent alopecia to cancer patients in Canada and Europe. However, Taxotere’s U.S. label only included a warning that “hair generally grows back.” The plaintiffs allege that this warning is vague and insufficient.
The Taxotere lawyers at TheLawFirm.com are hopeful that the defense will focus less on preparing for trial and more on resolving the cases. If you took Taxotere and suffered permanent hair loss as a result, contact us for a free consultation.
Update: April 21, 2017
The Taxotere attorneys at TheLawFirm.com have learned that US District Judge Kurt D. Engelhardt has ordered a ‘science day’ in the Taxotere litigation. This litigation involves the allegations that Taxotere caused permanent hair loss among cancer patients. A science day is where a trial judge is taught the scientific issues, methodologies and vocabularies of the scientific issues in the litigation before them.
Taxotere was first approved to treat breast cancer in 1996 but it wasn’t until December 2015 that mention of permanent alopecia (hair loss) was included on the drug’s U.S. label. The manufacturer had been warning women in Europe and Canada of this risk before 2015. The plaintiffs in the Taxotere lawsuits claim that Taxotere is more likely to result in the permanent loss of hair compared to other chemotherapy drugs.
Judge Engelhardt has appointed plaintiff and defense settlement committees and called on the parties to focus less on preparing for trial and more on resolving the cases. The Taxotere attorneys at TheLawFirm.com hope the manufacturer of Taxotere compensates the thousands of women who suffered permanent baldness. If you took Taxotere, and now suffer from permanent baldness, contact the Taxotere attorneys at TheLawFirm.com for a free consultation.
Update: March 20, 2017
Lawsuits filed on behalf of women who allege they experienced permanent hair loss (alopecia) due to Taxotere chemotherapy continue to move forward. Over 750 of these cases are now consolidated in the U.S. District Court for the Eastern District of Louisiana.
The Judge responsible, Judge Kurt D. Engelhardt, has issued two more Pretrial Orders. In December, 2016, when there were far less cases filed in the MDL, Judge Engelhardt appointed plaintiff and defense settlement committees. This appointment suggests that the Court would prepare the parties to focus less on preparing for trial and more on resolving the cases.
The attorneys at TheLawFirm.com assert that these cases should resolve because we believe that Taxotere is more likely to result in the permanent loss of hair compared to other equally effective drugs. What makes it worse is that Sanofi-Aventis provided information regarding the potential for permanent hair loss to individual patients and regulatory agencies in Europe and Canada. Yet the U.S. label for Taxotere only included a generic, vague, and insufficient warning that “hair generally grows back”.
Update: February 23, 2017
The world continues to take notice of the dangers of Taxotere (a version of docetaxel), with the Institut Curie discontinuing use of the controversial drug last week. The Institut Curie, headquartered in Paris, is one the world’s leading media research centers specializing on the treatment of cancer.
The Feb. 16 press release said five fatal cases had of patients treated with Taxotere had been reported to the ANSM, France’s FDA equivalent, since August 2016, with the coming on Feb. 4.
"As a precaution, given the occurrence within an unusually short period of time, of these two similar cases at the Institut Curie and those at other healthcare facilities in France, the Institut Curie has stopped using docetaxel to treat breast cancer. It has been replaced with paclitaxel," reads the press release.
This is the just the latest blow for Taxotere defenders who have been faced with an avalanche of lawsuits in court regarding permanent hair loss from cancer patients who were given the chemotherapy drug during treatment but were not properly warned of its dangers. Hardly a new drug, Taxotere just “celebrated” 20 years of being on the U.S. market.
Taxotere is manufactured and advertised by Sanofi-Aventis as a breast cancer treatment drug and was approved by the U.S. Food and Drug Administration (FDA) back in May 1996. Sanofi-Aventis has marketed Taxotere as a safe, effective, and superior drug treatment when compared to other chemotherapy drugs. However, prior to its approval, Taxotere had actually been recommended for rejection by the FDA in 1994 due to its toxicity.
Lawsuits claim that Sanofi-Aventis has been aware of reports and studies linking Taxotere to permanent hair loss after chemotherapy since as far back as its approval in 1996.
TheLawFirm.com is now accepting cases for women who suffered permanent hair loss as a result of taking the breast cancer chemotherapy drug Taxotere. It is estimated that 75% of breast cancer patients were given Taxotere®. Unfortunately, 6.3% of Patients given Taxotere experienced permanent hair loss. In December 2015, the FDA issued a Taxotere label change warning of potential permanent hair loss.
TheLawFirm.com asserts that, despite having knowledge of the risk of permanent baldness, Taxotere manufacturer failed to adequately warn women or the medical community of this permanent side-effect. We believe that there were other, equally effective, drugs available to fight cancer that did not carry this result.
In fact, in 2009, the FDA demanded that Sanofi-Aventis (the manufacturer) stop marketing Taxotere as having better results than the competitor's’ drug - the same drug the Institut Curie switched to in mid-February.
However, Taxotere lawsuits allege that, despite knowledge of their drug’s connection with permanent chemotherapy hair loss, Sanofi chose to conceal this information from patients and the medical community.
Lawsuits allege that because Sanofi-Aventis marketed Taxotere as similarly safe and effective to other chemotherapy drugs, despite the increased risk of alopecia, thousands of patients have been exposed to Taxotere side effects, including permanent Taxotere hair loss risk.
Have you been the victim of side effect from Taxotere and want to speak to a qualified attorney about relief? TheLawFirm.com has specialized attorneys working specifically with clients on these claims who will give you a 100% no-cost, risk-free evaluation. Contact us today to learn more.
What’s the Big Deal with Hair Loss?
Don’t you love it when people ask you that question?
Given the choice, anyone would rather lose their hair than suffer from cancer. But there’s no reason why should ever have had to choose between these “options.”
That’s just the thing – neither you nor your doctor had enough information to make an informed choice, because the manufacturer of Taxotere was covering up.
Temporary hair loss is a common side effect of chemotherapy treatment for cancer. Permanent hair loss, however, is not.
Permanent hair loss – also known as alopecia – for women is a more serious matter than baldness in men. Losing your hair for good is a quality-of-life issue of the highest order.
Having breast cancer doesn’t mean having to lose your hair.
When breast cancer is detected early (Stage 0 or Stage I), the five-year survival rate is nearly 100%. But these patients are often prescribed Taxotere.
When breast cancer is detected at Stage II, the five-year survival rate is nearly 93%. But these patients are often prescribed Taxotere.
But neither Taxotere nor any other specific drug is required to survive any specific kind of cancer. In many cases, numerous chemotherapy drugs do the job just as well or better. Alternatives to Taxotere exist – they just don’t get prescribed as often, because Big Pharma markets drugs so aggressively.
We believe that Sanofi-Aventis covered up the fact that they knew Taxotere could cause permanent hair loss.
If you feel you have a case, contact us.
The lawyers at TheLawFirm.com are not doctors. But we will fight for your health just the same.
Taxotere lawsuit FAQ's
Is this a Class Action?
No. A class action is where one or two people represent everyone and make the decisions for you. In the Taxotere® case, each case is individual and you, with your attorney, make the decisions about the important events in your case like whether to enroll in a settlement program when it becomes available. In the legal world, this is called a "mass tort".
Do you sue my doctor?
No. We do not sue or make any claims against your doctors. We believe that the doctors are the victims of the greedy pharmaceutical corporations as well. In fact, we expect your doctor to be as outraged as we are.
Will I have to go to Court?
Probably not. With thousands of similar cases filed before yours, it is very unlikely that you will ever have to go to Court. While there are no guarantees, 99% of cases like this resolve in a settlement program.
Can I just wait to bring a claim?
Unfortunately it’s very dangerous to wait because the law places strict time limits on your ability to make a claim. The time limits vary from state to state so if you aren’t sure if you still have time to make a claim, give us a call and we’ll let you know.
Who makes Taxotere®?
Taxotere® is made by French pharmaceutical giant Sonofi whose worldwide home office is in Paris France, but they have enormous operations here in the United States. The 5th largest healthcare company in the world, their income in 2015 was 37 billion euros. (roughly 40+ billion U.S. Dollars).
Who is eligible for possible compensation?
There are four criteria: • You must be a woman who survived Stage I, II or III breast cancer;
• You must have been treated with Taxotere® through IV (no oral chemotherapy);
• You must have taken the drug before December 2015; and
• You must now suffer from permanent hair loss.
TheLawFirm.com can help determine whether you are eligible for a lawsuit. Please call for a free consultation.
Why does hair loss matter?
This matters because hair loss can be devastating to women. Hair loss is associated with lower self-esteem, decreased self-confidence, depression and other emotional and psychological consequences.
It matters because a corporation took a product to market that was no more effective than its competitor and refused to warn American women about this possible loss. They made money off the suffering of cancer victims.
Men might not care as much but women report feeling self-conscious, unattractive and socially crippled when they are permanently bald. What was expected to be a temporary side effect turned out to be a permanent disfigurement so the corporation could profit.
The matter boils down simply to this: the decision on what drug to take should be made with full information and disclosure. To hide the fact that a permanent side effect is possible, when an equally effective alternative is available, is inexcusable.
Isn’t hair loss part of any chemotherapy regimen?
It’s true that women who undergo cancer treatment expect that their hair might fall out. However, women are mostly told that it will grow back a few months after treatment ends. In the case of Taxotere®- which studies show is more likely than similar, and equally effective, chemotherapy drugs to result in permanent hair loss - women were never given the choice of another drug because they were not warned about this possible side effect.
Why do you believe the manufacturer is responsible for my hair loss?
Quite simply, there was another drug that was just as effective as Taxotere® in treating cancer. However, the manufacturer promoted Taxotere® as superior until the FDA in 2009 demanded that they stop claiming an “unsubstantiated superiority” of Taxotere®. There was no warning of the possibility of permanent hair loss in the United States until December 2015. However, in Europe and Canada, the company did warn women. We believe the evidence will show that the company was more concerned about market share than safeguarding women’s health.
How long will my case take?
We expect the manufacturer to fight us tooth and nail. These cases can take several years.
How much will this cost me?
TheLawFirm.com never charges you anything up front. We only get paid if we win your case. We also advance many ‘costs’. If your case settles, or you are awarded damages by a jury, we are re-paid those costs out of the settlement or award. Typical case costs could be filing fees, the cost of obtaining medical records and expert witnesses, for example. Feel free to talk to us about how we are paid and what costs are.
Bottom line: we will never ask you to send us money. Ever.
What can I recover in a lawsuit?
While money will not make you whole again, you may be eligible for compensation for:
• Mental anguish/ Emotional Distress;
• Loss of earnings and lost earning potential; and
• Medical bills, or psychological counseling.
• The amount of damages recoverable through a lawsuit depends on an individual harm suffered and other unique circumstances. It is impossible for us to give a precise number as to how much money you may be awarded.
Do you guys know what you are doing?
People don't usually ask us so bluntly but it's important to know you are well represented. So yes. Our team has been handling defective medical product cases since fen/phen in the 1990s, and since then we’ve been involved in many of the major medical recall claims including Baycol, Rezulin, Prempro, Vioxx, and Medtronic defibrillators, pelvic mesh cases, and all types of metal-on-metal hip implants. Many members of our team have represented victims of defective medical products or bad drugs for almost 20 years.
Taxotere Update - November 29th, 2016.
The Court in New Orleans continues to issue Orders in the Taxotere MDL. The next status conference will take place on January 27, 2017 at 10:00 a.m. Issues such as service on the Defendant, the form of pleadings, motion practice and the potential for a tolling agreement are being discussed. TheLawFirm.com continues to monitor the Orders of the Court.
Get Help Now!
TheLawFirm.com’s award winning lawyers have been featured in over 50 radio and television interviews including: